Autolus Therapeutics PLC Sponsored ADR

AUTL Healthcare Biotechnology

In the quarter to June 2026, revenue grew 118.4%, EPS grew 16.7% and free cash flow grew 67.6%, each against the same quarter a year earlier.

1.63 0.11 −6.32%
Market cap
$463.1M
P/E
0.0×
Fwd P/E
−1.7×
Dividend yield
—
F-score
3/9
Altman Z
−3.17
Beneish M
n/a
Dividend safety
n/a
Dec '17 Sep '18 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
— 0.00 — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Piotroski F-Score
— — — — — 5 4 1 5 3
Altman Z-Score
— 32.63 — 5.22 0.27 0.24 (1.37) (1.57) (1.04) (3.17)
P/S ratio
— 0.00 — 195.49 268.76 160.56 27.16 215.42 56.97 7.03
P/FCF ratio
— 0.00 — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
— 18.41 — 4.56 (1.78) 1.79 0.29 (6.37) (0.36) (6.27)
Beneish M-Score
— — — — (2.43) (2.83) (1.79) — — —
P/Operating CF
— (143.58) — (17.09) (16.62) (40.85) (12.20) (47.91) (15.81) (7.87)
P/B ratio
— 4.70 — 2.23 2.19 1.19 0.59 10.67 1.40 2.97
Price to Tangible BV
— 4.71 — 2.23 2.20 1.19 0.59 10.67 1.45 3.35
EV/Sales
— 0.00 — 130.93 208.41 34.33 (28.43) 180.58 5.68 3.90
EV/EBITDA
— 0.00 — 0.00 0.00 0.00 1.37 0.00 0.00 0.00
EV/Operating CF
— (24.42) — (3.75) (3.04) (0.68) 1.66 (6.85) (0.29) (1.04)
EV/FCF
— (18.97) — (3.16) (2.68) (0.63) 1.50 (6.34) (0.25) (0.91)
Quick Ratio
28.17 14.42 10.76 9.68 5.46 11.80 8.88 5.37 9.70 4.44
Current Ratio
1.07 15.13 11.05 9.98 5.86 12.15 9.18 6.15 10.88 5.94
Net Debt/EBITDA
6.29 4.42 3.80 1.33 0.64 1.88 2.67 1.11 2.31 1.16
Debt/Assets
0.00% 0.08% 0.08% 7.81% 17.19% 4.08% 3.92% 12.76% 6.34% 0.00%
Debt/Equity
0.00 0.00 0.00 0.09 0.24 0.05 0.06 0.43 0.12 0.00
Asset Turnover
0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.00 0.02 0.11
Operating CF/Net income
(0.08) 0.70 0.70 0.82 0.83 0.83 0.75 0.70 0.93 0.99
Capex/Depreciation
(2.87) (5.58) 0.00 (4.05) (2.59) (1.05) (1.46) (1.67) (4.51) (2.76)
Interest Coverage
— — (76.95) (57.46) (313.70) (149.32) (16.10) (3.99) (25.98) (7.38)
ROE
(64.50%) (35.57%) (18.34%) (50.81%) (61.13%) (54.30%) (48.64%) (101.61%) (81.91%) (94.98%)
ROA
(58.09%) (32.12%) (16.97%) (44.41%) (47.54%) (40.61%) (33.23%) (48.14%) (38.11%) (41.92%)
ROIC
0.00% (418.26%) 0.00% (136.01%) (98.66%) (537.42%) 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(682.49%) (17.50%) (19.30%) (49.06%) (70.55%) (40.37%) (35.90%) (78.51%) (33.96%) (67.49%)
Average Days of Receivables
0.00 0.00 0.00 3,831.24 6,317.80 4,101.47 1,661.09 0.00 0.54 116.32
Research and Development Expense of Revenue
0.00% 2,569.30% 0.00% 3,625.10% 7,865.19% 5,784.94% 1,845.19% 7,684.39% 1,367.94% 156.11%
Selling, General and Administrative Expense of Revenue
0.00% 1,619.76% 0.00% 1,356.67% 2,039.18% 1,367.60% 501.56% 2,752.94% 1,005.17% 174.93%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.03
Share Based Compensation of Revenue
— 480.81% — 1,038.93% 1,172.42% 426.48% 188.90% 659.84% 152.89% 19.15%
Graham Net Nets
— 0.20 — 0.35 0.24 0.68 1.32 0.01 0.51 0.05
Graham Number
— 0.00 — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
— (2.61%) — (21.82%) (30.87%) (38.15%) (83.96%) (17.40%) (36.60%) (54.27%)
Free Cash Flow Yield
— (4.19%) — (21.21%) (28.89%) (34.07%) (69.74%) (13.22%) (40.33%) (61.13%)
Revenue per Share
0.00 0.04 0.00 0.07 0.03 0.03 0.07 0.01 0.04 0.28
Operating CF per Share
0.07 (1.00) (1.00) (2.36) (2.28) (1.64) (1.18) (0.84) (0.81) (1.07)
Capex per Share
(0.06) (0.30) 0.00 (0.43) (0.28) (0.12) (0.11) (0.06) (0.14) (0.10)
Free Cash Flow per Share
0.01 (1.30) (1.00) (2.79) (2.57) (1.76) (1.30) (0.90) (0.94) (1.17)
Cash per Share
2.70 7.83 6.89 4.91 2.99 4.31 4.03 1.38 2.31 1.14
Shareholders Equity per Share
(0.08) 8.10 7.37 5.92 4.07 4.35 3.14 0.64 1.67 0.67
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
(0.08) 8.10 7.37 5.92 4.07 4.35 3.14 0.64 1.67 0.67
Free Cash Flow
0.49 (41.07) (31.54) (120.15) (132.44) (126.72) (123.15) (156.57) (241.09) (310.70)
Working Capital
0.38 242.14 211.89 224.27 163.35 318.40 379.41 230.57 600.19 362.48
Capital Expenditures
(2.87) (9.53) (9.53) (18.67) (14.68) (8.86) (10.84) (10.99) (34.82) (27.13)
Net Current Asset Value
(0.65) 241.54 211.40 200.56 112.78 254.71 234.17 11.40 305.53 24.98
EV/EBIT
— 0.00 — 0.00 0.00 0.00 1.30 0.00 0.00 0.00
Capex to Sales
0.00 6.77 — 6.42 8.56 3.80 1.70 6.47 3.44 0.36
Price to Operating Income
— 0.00 — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.16 0.13 0.09 0.16 0.15 0.25 0.21 0.19 0.16 0.15
Cash ROIC
0.37% (8.17%) (7.00%) (24.52%) (31.94%) (19.78%) (17.58%) (39.17%) (22.61%) (64.68%)
Accounts Receivable Turnover
0.00 0.00 0.00 0.15 0.06 0.08 0.23 0.00 0.70 6.27
Accounts Payable Turnover
0.00 0.00 0.68 2.98 0.00 0.00 0.00 0.00 10.99 38.15
Inventory Turnover
0.00 — 0.00 0.00 — — — — 0.00 5.16
Average Days of Payables
0.00 0.00 431.85 85.10 0.00 0.00 0.00 0.00 63.11 11.68
Days of Inventory on Hand
0.00 — 0.00 0.00 — — — — 132.64 125.78
Average Receivables
3.46 — 7.00 19.89 30.10 27.93 27.56 — 14.48 12.02
Average Payables
— 2.49 2.53 1.55 1.67 1.35 0.48 0.32 1.04 2.53
Average Inventory
— — — — — — — — — 18.67
Average Assets
77.04 139.31 263.71 278.87 298.89 349.90 447.92 432.83 579.05 685.90
Average Common Equity
69.38 125.81 244.05 243.74 232.44 261.68 306.00 205.07 269.40 302.73

Fold the line items

Columns are period end dates · fundamentals updated 28 Sep 2026